✨
AI Summary
- GLP-1 agonists are booming for obesity treatment.
- Opportunity for consumer health in pre-diabetes and wellness.
- Kerry Group's Mathieu Millette shares insights.
Guests on This Episode
MM
Mathieu Millette
1 podcast appearance